- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06131801
Estudio farmacocinético de tabletas de Venetoclax trituradas y disueltas en una solución
Un estudio farmacocinético de tabletas de Venetoclax trituradas y disueltas en una solución en niños y adultos jóvenes con neoplasias hematológicas
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.
Primary Objectives
• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution
Secondary Objectives
- To evaluate the safety of crushed venetoclax tablets administered as an oral solution
- To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors
- To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)
- To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution
Descripción general del estudio
Estado
Condiciones
- Linfoma
- Linfoma folicular
- Leucemia
- Linfoma de células B
- Linfoma de Hodgkin
- Linfoma de Burkitt
- LMA
- No linfoma de Hodgkin
- Leucemia linfocítica aguda
- Leucemia mielógena aguda
- Linfoma difuso de células B grandes
- Malignidad hematológica
- Leucemia mielógena crónica
- Neoplasia mieloproliferativa
- Linfoma de células T
- Linfoma periférico de células T
- LMC
- TODOS
- Linfoma cutáneo de células B
Descripción detallada
Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Site Public Contact
- Número de teléfono: (513) 636-2799
- Correo electrónico: cancer@cchmc.org
Ubicaciones de estudio
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- Children's Hospital Colorado
-
Investigador principal:
- Kelly Faulk, MD
-
Contacto:
- Kelly Faulk, MD
- Número de teléfono: 720-777-5771
- Correo electrónico: Kelly.Faulk@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Aún no reclutando
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital
-
Contacto:
- Himalee Sabnis, MD, MS
- Número de teléfono: 57922 404-785-3627
- Correo electrónico: Himalee.sabnis@choa.org
-
Investigador principal:
- Himalee Sabnis, MD, MS
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Reclutamiento
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Children's Hospital of Philadelphia
-
Investigador principal:
- Sarah Tasian, MD
-
Contacto:
- Tasleema Patel
- Número de teléfono: 917-818-6971
- Correo electrónico: patelt6@chop.edu
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Texas Children's Hospital
-
Contacto:
- Michelle Redell, MD
- Número de teléfono: 832-822-4242
- Correo electrónico: mlredell@texaschildrens.org
-
Contacto:
- Grace Anand
- Número de teléfono: 832-824-7705
- Correo electrónico: gxanand@texaschildrens.org
-
Investigador principal:
- Michelle Redell, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Children's Hospital of Wisconsin
-
Investigador principal:
- Zachary Graff, MD
-
Contacto:
- Kira Mielke
- Correo electrónico: kmielke@mcw.edu
-
Contacto:
- Kara Nelson
- Correo electrónico: knelson@mcw.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
Patients must be <39 years of age at time of study enrollment.
Descripción
Inclusion Criteria:
- Age: Patients must be <39 years of age at time of study enrollment
- Diagnosis: Patients may have a diagnosis of any hematologic malignancy
- Central access: Patients must have an existing venous or arterial access line for PK blood draws
- Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
- Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
- Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.
Exclusion Criteria:
- Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
- Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: OTHER
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Children and Young Adults
Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care. |
Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Periodo de tiempo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Periodo de tiempo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the time to peak (Tmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Periodo de tiempo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the apparent terminal phase elimination rate constant (β) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Periodo de tiempo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the terminal-phase elimination half-life (T1/2) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Periodo de tiempo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Periodo de tiempo: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: oral clearance (CL/F) of venetoclax |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Periodo de tiempo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Periodo de tiempo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the time to peak (Tmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Periodo de tiempo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the apparent terminal phase elimination rate constant (β) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Periodo de tiempo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the terminal-phase elimination half-life (T1/2) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Periodo de tiempo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Periodo de tiempo: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: oral clearance (CL/F) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias por sitio
- Neoplasias
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Infecciones
- Enfermedades virales
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Infecciones por virus de ADN
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Leucemia Mieloide
- Enfermedades de la médula ósea
- Leucemia Linfoide
- Infecciones por el virus de Epstein-Barr
- Infecciones por herpesviridae
- Infecciones por virus tumorales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Leucemia
- Leucemia Mieloide Aguda
- Neoplasias Hematológicas
- Linfoma
- Linfoma de células B
- Linfoma de células B grandes, difuso
- Leucemia-linfoma linfoblástico de células precursoras
- Linfoma de Burkitt
- Linfoma No Hodgkin
- Linfoma Folicular
- Trastornos mieloproliferativos
- Enfermedad de Hodgkin
- Linfoma de células T
- Linfoma De Células T Periférico
- Leucemia, Mielógena, Crónica, BCR-ABL Positivo
Otros números de identificación del estudio
- Venetoclax PK
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .